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INTRODUCTION
On 31 December 2019, the World Health Organization 
(WHO) reported a cluster of pneumonia cases in Wuhan City, 
China. The majority of the patients initially identified were 
dealers and vendors at a seafood, poultry and live wildlife 
market in that area. “Severe Acute Respiratory Syndrome 
Coronavirus 2” (SARS-CoV-2) was confirmed as the causative 
agent of what we now know as “Coronavirus Disease 2019” 
(COVID-19). Since then, the virus has spread to 213 countries 
and territories around the world with a total of 6  177 120 
confirmed cases and a death toll of 371 287 deaths as of 
31 May 2020.(1) At the beginning of the pandemic, travellers to 
areas with ongoing sustained transmission of COVID-19 were 
at greatest risk of infection, but it has now extended to local 
and community transmission. Furthermore, the elderly, indivi-
duals with co-morbidities, especially cardiovascular disease,(2) 
and healthcare workers have been found to be at a higher risk 
of death. We are in the midst of the most serious global health 
crisis of our generation, with a significant and far-reaching 
impact upon health, economy, social cohesion and emotional 
and mental wellbeing.
In a recent systematic review of the ever-increasing literature, 
45 relevant scientific papers and letters noted that not only 
have children so far accounted for only 1% - 5% of diagnosed 
COVID-19 cases, they also have milder disease than adults and 
deaths have been extremely rare. Although diagnostic findings 
have been similar to adults, with fever and respiratory symptoms 
being prevalent, fewer children seem to have developed severe 
pneumonia, elevated inflammatory markers were less common 
in children, and lymphocytopenia seemed rare.(3) New-born 
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Coronavirus 2 (SARS-CoV-2) the causative agent of 
what we now know as “Coronavirus Disease 2019” 
(COVID-19), is the most serious global health crisis of 
our generation, with a signifi cant and far-reaching 
impact upon health, economy, social cohesion and 
emotional and mental wellbeing. Although children do 
not bear the brunt of direct mortality, they are signi-
fi cantly affected in terms of morbidity and interruption 
to access, continuity and complexity of care, as well as 
the indirect social and fi nancial effects impacting on 
their health outcomes. In this review we present some 
of the most recent data relevant to children with 
congenital and acquired heart disease, and consider 
some of the cardiac presentations noted. We discuss 
the necessary protections to staff in the echo and 
cardiac catherisation laboratories and present some 
general recommendations to general paediatricians 
and communities to ensure the continued health of 
our patients. Finally, we encourage ongoing registries 
and biorepositories and support clinical trials to ensure 
that children also receive new technologies and thera-
peutics as these become available.  
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infants have developed symptomatic COVID-19, but evidence 
of vertical intrauterine transmission is scarce.(4) Even in high 
mortality communities, such as China, Italy and Spain, the low 
incidence in children and decreased mortality and improved 
outcomes have been sustained. However, the paediatric 
population in South Africa have differing clinical characteristics 
and profile, with possible implications for risk in this population. 
Of interest, in particular, are children with underlying immune 
compromising illness such as HIV and TB, underweight and 
malnourished children, and those with underlying chronic 
medical conditions.(5) As the South African paediatric cardiology 
community, we are deeply concerned as the impact of SARS-
CoV-2 – both directly and indirectly – is as yet unknown. The 
complete clinical picture with regard to paediatric COVID-19 
is still not fully clear and nuances in children have not been 
comprehensively reported or defined.(6) Atypical presenta-
tions in children include a Kawasaki-like picture and unusual 
cutaneous lesions.(7-11)
Treatment currently is only supportive with no specific antiviral 
treatment available. There are few data regarding treatment 
with adjunctive therapies such as steroids, hydroxychloroquine, 
intravenous immunoglobulins amongst others in children, and 
there is a real need for evidence-based directed therapies, 
interventions and medical management. In a review of 1 391 
children tested for COVID-19 in Wuhan, China, a total of 171 
(12.3%) were confirmed to have SARS-CoV-2 infection. 
Outcomes were good with only one mortality.(12) As children in 
our setting have vastly different socio-economic backgrounds 
to these children, with potential effects from HIV-exposure and 
infection and a high TB prevalence rate, it is critically important 
to review our population, their outcomes and consider con-
textualised treatment and management strategies. This manu-
script, prepared prior to seeing large numbers of children with 
COVID-19, reviews some of the literature to date, focusing on 
some of the clinical presentations relevant to our speciality, 
considers some of the potential areas of impact on our patients, 
suggests intervention and protection measures, and concludes 
with f inal suggestions to our community and to general 
paediatricians/practitioners and patients. 
BACKGROUND
Very few children have a poor outcome following SARS-
COV-2 infection. Shekerdemian and colleagues reported the 
North American paediatric intensive care experience during a 
three week period in March 2020.(13) Only 48 patients were 
collected from 46 participating units, 73% of these children had 
a respiratory illness and 40 of the 48 had underlying medical 
conditions. Only 2 of this cohort died during the period under 
review. “Adult” risk factors such as obesity also applied to 
these younger individuals. There are too few data available to 
establish whether underlying heart disease in children confers 
an increased risk of developing severe COVID-19. 
Recently, during the decline in the new infection phase in areas 
of major outbreaks, reports of unusual presentations involving 
the cardiovascular system in children have appeared. Italian 
authors reported that patients with Kawasaki disease (many 
associated with documented coronavirus infection) were seen 
30 times more commonly in the North of Italy in the first few 
months of 2020 than in the 5 previous years.(14) Ten patients 
were described. They were generally older than typically 
reported, with a median age of 7.5 years. Half of the children 
had typical Kawasaki disease, and half were reported as having 
“Kawasaki shock syndrome” (KSS) with hypotension as part of 
the presentation. Five children had “macrophage activation 
syndrome” (MAS). Three children had both KSS and MAS.
A more severe illness attributed to a cytokine storm similar to 
that seen in adults was also noted to be occurring in children 
(sharing features seen in the Italian publication) in April 2020. 
Frustratingly for health personnel, the reports appeared simul-
taneously in the lay press and societal bulletins, before details 
emerged in scientific journals. Fortunately, the facilitation of 
information sharing from professionals in affected areas fol-
lowing the widespread use of easy-to-use videoconferencing 
software (arguably one of the few benefits of lockdown), has 
countered the lack of information in the professional press. A 
number of terms – multisystem inflammatory syndrome in 
children (MIS-C), paediatric inflammatory multisystem syn-
drome temporally associated with SARS-COV-2 (PIMS-TS) 
and paediatric COVID-associated Multi-system Inflammatory 
Syndrome (PMIS)(15-17) – have been applied to the acute and 
potentially life-threatening illness typified by a delayed pre-
sentation with hypotension rather than respiratory illness. The 
condition has been associated with few deaths, however a 
few patients have required extracorporeal membrane oxy-
genator support in order to survive.(18) Therapy of patients 
has included the use of inotropic support, immunoglobulin 
infusions, high dose steroids and the recombinant IL-1 receptor 
antagonist Anakinra.(19) 
Much information can be gleaned from short case series or 
individual case reports.(20,21) While patients with typical 
“Kawasaki like illness” are described,(20) more patients have 
been described who present with gastrointestinal symptoms, 
troponin leak and cardiac dysfunction and thrombocytopenia, 
which are not as commonly described in KSS.(21) These patients 
often do not have a respiratory illness and do not have viral 
RNA detected in respiratory secretions; evidence of corona-
340
EFFECTS OF COVID-19 ON CHILDREN
virus infection is determined by the presence of antibodies to 
SARS-COV-2.(17)
These features have prompted Stanford Shulman, the distin-
guished infectious disease expert, to opine that while the 
occasional patient has true Kawasaki disease, the majority of 
children presenting with the severe illness after infection have a 
similar illness to adult patients who have been described as 
having a cytokine storm.(17)
MYOCARDIAL INVOLVEMENT
There are few data available specifically regarding myocardial 
involvement in children with COVID-19 infection. The Chinese 
Centre for Disease Control and Prevention reported 2% out 
of 72 314 cases infected by the COVID-19 virus were less 
than 19 years of age.(22) 
The SARS-CoV-2 virus has a similar binding domain to SARS-
CoV which attaches to human cells after binding to angiotensin 
converting enzyme 2 (ACE2), a peptide which is expressed 
by epithelial cells of the lung, intestine, kidney, and blood 
vessels.(23,24) ACE2 has a similar structure to angiotensin con-
verting enzyme (ACE), but unlike ACE is responsible for the 
cleavage of Angiotensin II into metabolites that have vasodila-
tory, anti-fibrotic and anti-hypertrophic roles. ACE2 also has 
immunomodulatory properties indirectly reducing angiotensin 
II, which tends to cause inflammation. Downregulation of 
ACE2 activity occurs once binding to cells is complete. ACE 2 
has a protective role and heightened angiotensin II activity 
secondary to its down regulation may be a mechanism leading 
to cardiac and/or lung injury in COVID-19 infections.(24)
Several significant differences in the frequency of distribution of 
ACE2 variants among different racial and ethnic lines have 
been described. Serum levels of ACE2 have also been nega-
tively correlated with body mass index, pulse pressure, and 
oestrogen levels.(25) There is a cardio-protective effect of cir-
culating ACE2 and oestrogen participates in the upregulation of 
ACE2 activity levels, which may explain the susceptibility of 
males to COVID-19.(26) Children also have higher levels of 
ACE2 than adults.(27) ACE2 can pass through the placenta, 
enabling the mother to transfer to her baby her immunity and 
other forms of protective soluble factors.(28)
Overt involvement of the myocardium in children is uncom-
mon and has been suggested by the presence of elevated myo-
cardial enzymes which were shown in 31% of 36 children as 
part of routine laboratory testing in one study.(28) Leukopenia, 
lymphopenia, and increased myocardial enzymes were noted 
in both children and adults with a similar frequency. Adult 
patients, however, showed an increased C-reactive protein 
response compared with children, suggesting a milder immuno-
logical response in children.(28) 
The manifestation of myocardial injury in adult patients with 
COVID-19 has been shown to vary in severity. Some patients 
are asymptomatic and may only be detected by laboratory 
markers such as raised cardiac troponin levels, which if very 
elevated, is prognostic for in-hospital mortality. Myocardial 
involvement has been shown to manifest clinically with chest 
pain caused by myocardial ischaemia or myocarditis, palpita-
tions and acute heart failure. Heart failure is commonly 
associated with cardiovascular comorbidities, and is frequent 
in patients who die with COVID-19 infection.(29,30) 
Few cases with confirmed myocarditis and COVID-19 infection 
have been reported. Endomyocardial biopsies have shown 
that the virus can be present, but may not necessarily have a 
pathogenic role in some cases.(31) An indirect method of myo-
cardial injury related to an inflammatory or oxidative stress in 
the setting of COVID-19 infection is suggested in the case of 
reversed Takotsubo cardiomyopathy, where the endomyo-
cardial biopsy (EMB) showed a diffuse T-lymphocytic inflam-
matory infiltrate associated with limited focal necrosis without 
the SARS-CoV-2 genome being detected. An alternative expla-
nation for the absence of finding the virus present is that 
EMB has a potential sampling error. It is likely that with more 
autopsy evidence, COVID-19 related viral myocarditis may 
emerge.(24,32-34)
EFFECTS ON THE CONDUCTION TISSUE
An indirect effect on the conduction tissue in patients with 
COVID-19 infection has been documented with treatment 
using hydrochloroquine, which has antiviral efficacy against 
SARS-CoV-2. The combination of azithromycin and hydro-
chloroquine has a synergistic effect and  is associated with 
severe QT prolongation and the potential for torsade de 
pointes.(34) A recent systematic review was unable to confirm a 
benefit of hydroxychloroquine or chloroquine, when used 
alone or with a macrolide, on in-hospital outcomes for 
COVID-19.(35) However, each of these drug regimens was 
associated with decreased in-hospital survival and an increased 
frequency of ventricular arrhythmias when used for treatment 
of COVID-19. Cases of bradyarrhythmias have been docu-
mented in adult patients, including sinus node dysfunction(36) 
and transient complete heart block.(37)
Myocardial and conduction tissue involvement may become 
more evident as the COVID-19 pandemic evolves and more 













protected and experience mild symptoms, the possibility of 
myocardial involvement with associated ventricular dysfunction 
and dysrhythmias should not be overlooked.
THE IMPACT ON CONGENITAL HEART 
DISEASE IN SOUTH AFRICA
Accurate birth and community prevalence of congenital heart 
disease (CHD) is lacking in South Arica. Estimating from current 
live birth rates, approximately 2 500 children with significant 
CHD requiring intervention are born annually, contributing to 
the considerable pool of patients with “corrected”, palliated, 
uncorrected and undetected CHD within communities in the 
country. 
Current consensus is that in the vast majority of cases of 
children infected with SARS-COV-2 are asymptomatic or mildly 
symptomatic.(3,38,39) Available information suggests that children 
with underlying conditions appear to be among those at 
higher risk of severe disease. The numbers of those becoming 
seriously ill and requiring hospitalisation are, however, still far 
fewer than adults with cardiovascular disease and the specific 
risk for CHD remains unclear. 
Extrapolating from experiences with seasonal viral illnesses, the 
best studied being RSV,(40) COVID-19 infection would be 
expected to have more serious manifestations in haemo-
dynamically significant congenital heart disease. Expected pre-
sentations include: 
 ■ Increasing respiratory distress in conditions that manifest 
with heart failure – left to right shunts such as ventricular 
septal defects, patent arterial duct and more complex 
common mixing conditions. Hepatomegaly and car-
diomegaly – both clinically and radiographically, should alert 
the clinician to a cardiac cause. Cardiac murmurs are not 
always prominent, particularly in patients with the largest 
shunts and associated pulmonary hypertension. The lung 
changes caused by pulmonary plethora or pulmonary 
venous congestion may not always be differentiated by a 
primary care physician from that of COVID-19 or other 
disease processes. 
 ■ Increasing cyanosis or hypercyanotic episodes: Deteriora- 
tion could be expected in patients with Tetralogy of Fallot 
or similar lesions with decreased pulmonary blood flow 
related to reduced systemic vascular resistance and 
worsening right to left shunting, with or without acute 
pulmonary disease. 
Immunosuppressed patients expected to have more severe 
disease include those CHD patients with underlying Trisomy 
21, 22q11 deletion with thymic aplasia/hypoplasia, as well as 
heterotaxy patients who in addition to complex congenital 
cardiac lesions may have anatomical or functional asplenia. 
Adolescent and in particular adult patients with untreated as 
well as palliated CHD have increased vulnerability and reduced 
functional reserve. These include Eisenmenger syndrome and 
patients post univentricular palliation and atrial switch pro-
cedures. Pregnancy represents a particularly vulnerable period 
for these women and there is a concern that difficulty in acces-
sing healthcare could result in poor maternal outcomes.(41,42)
In the face of the pandemic, the greatest threat to child health 
is likely from the disruption of current healthcare systems.(43) 
Disruption already seen within the paediatric cardiac services 
includes:
 ■ Postponement of elective clinic visits, surgery and cardiac 
catheterisations to reduce hospital and clinic volumes.  
 ■ Reduced access to healthcare services: Poor availability and 
increased cost of transport coupled with reduced house-
hold incomes, as well as confusion regarding safety and 
legality of movement has increased the number of patients 
missing essential visits and filling of their prescriptions. 
Limited internet and cell phone access reduces the utility 
of remotely filling prescriptions and “teleconsultations”. 
CHD patients are at increased risk of severe disease from 
vaccine-preventable disease outbreaks due to reduced 
immunisations.
 ■ The reluctance of patients requiring urgent interventions 
to be admitted for fear of contracting COVID-19 infection 
in hospital, has been exacerbated by reduced bed avail-
ability for boarder mothers in some hospitals as well as 
the prohibition or severe restriction of visitors in most 
institutions.
Should the pandemic progress as anticipated and services be 
overwhelmed or strained, surgical and catheter interventional 
services are likely to be further reduced or suspended. This will 
compound the existing burden of undetected and untreated 
CHD contributing to the significant mortality and morbidity of 
these patients.(44) 
Rheumatic Heart Disease (RHD) is thought to affect at least 
39 million people worldwide with the majority of these being 
young people, living in low- and middle-income countries and 
disproportionally affected by poverty, vulnerable health systems 
and poor access to tertiary medical and surgical interven-
tions.(45) It is therefore most likely that patients with RHD will 
experience challenges during this period, both directly and 
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indirectly. The need for ongoing medical care, as with all 
chronic conditions, is particularly relevant to this population as 
a crucial part of prevention is regular monthly secondary 
prophylaxis.(46) Accessing this may be difficult or even impossible 
during this time. For those requiring ongoing medical treat-
ment or therapeutic management of e.g. INR for those on 
warfarin, missing an appointment or blood test may result in 
life-threatening complications. The inability to access repro-
ductive healthcare and contraception during this period can be 
associated with severe outcomes in women with prosthetic 
valves or mitral stenosis, as raised in the REMEDY study.(47) 
CARDIAC CATHETERISATION AND 
INTERVENTIONS
Pediatric cardiology units are challenged for case selection 
during the COVID-19 pandemic. This can be ascribed to the 
paucity of guidelines, apparent lower impact of the virus in the 
pediatric population, limited scientific data and the unprece-
dented strain on hospital resources as a result of the corona-
virus crisis.(48) Therefore, congenital cardiac programmes should 
be equipped to face a number of unique and fluid scenarios to 
deal with patients as the situation enfolds.
Although no definite recommendations exist for paediatric 
CHD patients, certain common themes are apparent in current 
literature and should be considered in congenital cardiac pro-
grammes during the pandemic.(49-53)
Protection of resources
Given the limited supplies of personal protective equipment 
(PPE), testing capability and ventilators, it is recommended to 
limit or postpone elective cases in order to make more of 
these valuable medical resources available for those in need. 
Local disease burden and changing patterns of disease put 
emphasis on the need for serial re-evaluation and situational 
analysis with appropriate adaptation of strategy. A proposed 
strategy for case selection is presented in Table 1. It should 
be recognised that each situation is unique, and management 
should be individualised; categorisation is no substitute for 
sound clinical judgment. It is also advisable that decisions should 
be discussed and coordinated with the local COVID-19 task 
team and/or departmental ethics committee.
Limiting exposure
In order to protect patients and catheterisation laboratory staff, 
exposure risks should be minimised. Compliance with social 
distancing and general infection control measures should be 
strictly adhered to. Algorithms should be developed and 
clearly communicated. Screening of patients is advised, but 
strategy should be determined by local resources and avail-
ability of adequate viral testing supplies. In a United States 
survey of congenital heart centres, Morray, et al. found that 
65% of centres only screened for COVID-19 prior to cardiac 
catheterisation in the presence of symptoms of a viral pro-
drome; in this study merely 15% of centres screened all their 
patients.(52) It thus seems reasonable to make meticulous use 
of the COVID screening tool for all patients when cardiac 
catheterisation is indicated.
Use of PPE is vital to protect healthcare workers. Excellent 
resources are available to guide physicians in the management 
of patients with COVID-19 as well as donning and doffing of 
PPE.(50) These should be readily available and areas for donning 
and doffing should be clearly demarcated. It is advisable to do 
“test runs” and training to familiarise echocardiography and 
catheterisation laboratory personnel with patient management 
and correct donning and doffing techniques. 
Limiting the number of staff (including trainees) in the cardiac 
catheterisation laboratory to the minimum is a logical pre-
caution. This is even more important during aerosol generating 
procedures such as airway manipulation – ideally, a separate 
anaesthesia team should be dealing with this. Due to the limited 
number of healthcare professionals able to deal with congenital 
TABLE I: Approach to cardiac catheterisation case selection.
Category Urgent Intermediate Elective
Time frame* Urgent 1 - 2 months >3 months
Indicators Impending haemodynamic 
compromise if not treated
Symptomatic or asymptomatic, but 
undue delay could be detrimental
Waiting period will not 
lead to undue harm
Examples# Septostomy for TGV, PDA/RVOT stenting 
for decreased pulmonary blood fl ow, 
critical valvar lesions, etc.
PDA with heart failure, etc. ASD device closure, PDA where heart 
failure can be controlled, pre Fontan 
evaluation, etc.
*Time frame – period for action; this must be individualised and based on clinical judgement.
#Note that examples are not absolute or limited to those given. Clinical judgment/patient safety should always take preference.













cardiac disease, consideration should be given to splitting staff 
into 2 or more groups with the aim of ensuring at least 1 
unexposed group in the event of COVID-19 exposure, in 
order to safeguard continuation of service.
Proper decontamination of the catheterisation laboratory after 
use is essential. Attention should be paid to the air-conditioning 
system and preferably a negative pressure room with the 
correct frequency of air changes should be used. 
In the end, each congenital cardiac unit should decide how to 
best serve their community based on local/regional disease 
prevalence and availability of medical resources. By adhering 
to the principles described above, risks may be reduced for 
patients and staff.
CONCLUDING REMARKS
The COVID-19 pandemic represents the most important 
public health crisis of our lifetime. Moreover, its socioeconomic 
impacts, especially in the low to middle income countries like 
South Africa will be felt for many years to come. In South 
Africa, access to paediatric cardiac services is a challenge for the 
majority of our patients. This is due to a number of socio-
economic and geographical reasons previously described by 
Hoosen et al.(44) The majority of paediatric cardiology services 
are offered in big academic hospitals catering for adults as well. 
As the pandemic surges, hospitals may prioritise the treatment 
for critically ill adult COVID patients, thus posing an ethical 
dilemma for the children with urgent and worsening CHD 
needing intervention.(54)
Mortality due to COVID-19 in children is reportedly low, with 
only few reported deaths. However, it would be prudent to 
assume that those with severe CHD are at higher risk of 
having severe COVID-19. Notably, the British Congenital 
Cardiac Association (BCCA) issued a statement to identify 
people with congenital heart disease who are at particularly 
high risk of becoming seriously ill from COVID-19 corona-
virus.(55) The list included those patients with complex con-
genital heart disease (such as single ventricular physiology), 
patients with severe pulmonary hypertension, chronic cyanosis, 
unrepaired congenital cardiac lesion, and those with asso-
ciated immunosuppression (e.g. such as trisomy 21, 22q 
deletion). It is important to ensure that patients continue to 
take the prescribed cardiovascular medications as the studies 
published have not shown any interference of this virus with 
these drugs.(54) As caregivers, we need to provide guidance to 
patients, parents and community, as well as those referring 
patients to our services (Table 1I). Global Arch together with 
Children’s Heart Link has also issued the following guidelines: 
http://www.global-arch.org/covid-19-what-you-need-to-know/.
Appropriate management of this pandemic requires a careful 
coordinated approach involving various stakeholders who are 
all equally important. It is imperative that the Department of 
Health (DOH), National Institute for Communicable Diseases 
(NICD), cardiovascular societies or associations and local 
hospitals, should join forces in order to navigate this precarious 
period. During the pandemic, risk of transmission from patient 
to healthcare worker, healthcare worker to patient and health-
care worker to healthcare worker poses a major challenge. All 
referrals should be screened even at the time of discussion 
with referring colleagues prior to transportation. Therefore, 
TABLE II: Advice and key messages.
General community 
General practitioners and 
referring paediatricians 
Patients and parents
All children should receive their routine 
vaccinations during this time.
All children should be protected, and good food, 
exercise and regular activity should be encouraged.
Children should not be separated from their 
parents if at all possible, with special emphasis on 
the breastfeeding infant.
We support the role of schools (and the 
workplace) beyond just education: activity, social 
interaction but also food provision and protection 
from household violence. However, in the case of 
high-risk cardiac patients, the benefi t of return to 
school should be carefully balanced against the risk 
of severe infection. 
Cardiology services are still open albeit 
curtailed – speak to your local cardiologist if 
concerned
Shortness of breath in children must be 
considered as a cardiac symptom, not only of 
COVID-19.
Consider vaccination against the infl uenza virus 
and Palivizumab for the respiratory syncytial virus 
in infants, if available
Discuss COVID-19 status of patient PRIOR to 
referral to a tertiary centre
We stress the importance of continuing with 
current medication.
Contact your cardiologist if you are have an 
upcoming appointment – some of these 
appointments can be done remotely.
Contact your cardiologist prior to coming to 
hospital if possible. Each hospital has new 
protocols regarding admission and screening 
upon arrival. 
High-risk cardiac children (complex defects, single 
ventricle), severe cyanosis, reduced cardiac 
function or heart failure, arrhythmias, pulmonary 
hypertension, heart surgery within the last 3 
months or heart transplant patients should 
continue to be seen regularly.
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universal precautions with frequent handwashing, social dis-
tancing measures, proper and appropriate use of PPE, and 
cleaning and disinfecting commonly touched surfaces, should be 
practised at all times. 
EDUCATION AND FUTURE DIRECTIONS 
In every crisis there is an opportunity to learn new things and 
explore novel ideas. Telemedicine has to be employed for 
patients’ consultations and clinical case conferences with col-
leagues. It is imperative that service providers work together 
to ensure data are gathered on the number of patients tested, 
those diagnosed with the infection, and their outcomes. As we 
continue to learn more about the epidemiology, clinical mani-
festations and treatment protocols for COVID-19 in children, 
we should be responsive to new information, as this now 
emerges almost daily. However, data may be published in the 
lay press prior to peer-review or scientific substantiation, and 
care should be taken in this regard. We should use this 
opportunity to establish national registries and explore and 
support clinical trials, so that children, often forgotten, can also 
benefit from any emerging therapeutics or technologies.
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